Breaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeekBreaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeek
  • Home
  • Nation
  • Politics
  • Economy
  • Sports
  • Entertainment
  • International
  • Technology
  • Auto News
Reading: Nifty Pharma Dips 0.75% as Analysts Weigh Mixed Outlooks
Share
Breaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeekBreaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeek
  • Home
  • Nation
  • Politics
  • Economy
  • Sports
  • Entertainment
  • International
  • Technology
  • Auto News
© 2024 All Rights Reserved | Powered by India News Week
Trending Now: Stay updated with the latest breaking news from India and around the world
Nifty Pharma falls 0.75% as most stocks decline amid mixed analyst views 
Breaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeek > Economy > Nifty Pharma Dips 0.75% as Analysts Weigh Mixed Outlooks
Economy

Nifty Pharma Dips 0.75% as Analysts Weigh Mixed Outlooks

Economy Desk By Economy Desk September 28, 2025 2 Min Read
Share
SHARE

The Nifty Pharma index is currently trading at 22,015.30, reflecting a decline of 165.40 points or 0.75% from its previous close of 22,180.70, as the trading day nears its conclusion. The index initially opened higher at 22,219.65 but experienced considerable selling pressure throughout the session, hitting an intraday low of 21,983.20.

Market breadth remained unfavorable, with 15 stocks declining compared to just 5 advancing. Among the major laggards, Ajanta Pharma reported a drop of 2.04%, Torrent Pharma decreased by 1.86%, and Dr. Reddy’s fell by 1.66%. Notably, Cipla led the losses with a 1.64% decline to ₹1,512.70, making it the most actively traded stock by value, with transactions totaling ₹336.07 crores.

On a more positive note, Glenmark Pharma emerged as the top gainer, rising by 1.03% to ₹2,039.40 following its licensing agreement with Hengrui Pharma for the oncology drug Trastuzumab Rezetecan. Aurobindo Pharma and Mankind Pharma also reported modest gains during the trading session.

Analyst sentiment within the sector remains mixed. Motilal Oswal maintains a buy rating on Gland Pharma with a target price of ₹2,340, citing potential performance revival due to niche approvals in the U.S. In contrast, Morgan Stanley has assigned an overweight rating to Sun Pharma, with a target of ₹1,948, underscoring the company’s preparations for the GLP-1 market. However, Nomura has adopted a neutral stance on Glenmark despite the recent licensing agreement, setting a target price of ₹1,500.

Over the longer term, the pharma index has displayed resilience, achieving 74.58% returns over the past three years, despite recent downturns.

TAGGED:Economy NewsNews
Share This Article
Twitter Copy Link
Previous Article Focus Tamil Nadu | Is Rajinikanth inseparable from controversies? Rajinikanth: A Bollywood Icon Always Entangled in Controversies?
Next Article US pressures India on Russian oil imports; MEA slams tariffs as unfair, reiterates energy security US Urges India to Cut Russian Oil Imports Amid Energy Security Concerns
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Latest News

India world's best long-term investment destination, FDI rises 20% in April-September: ITPO Chairman

India Emerges as Top Long-Term Investment Hub with 20% Rise in FDI, Says ITPO Chairman

November 18, 2026
SEBI cuts commodity trading margins; new rates effective December 1, 2026

SEBI Lowers Commodity Trading Margins with New Rates Starting December 1, 2026

November 17, 2026
Rupee rises 43 paise to close at 93.51 (provisional) against US dollar

Rupee Gains 43 Paise, Ends at 93.51 Against US Dollar in Provisional Close

November 17, 2026
India’s compressed biogas potential, production targets and blending obligation

Unlocking India’s Biogas Potential: Production Goals and Blending Obligations Explored

November 17, 2026
India raises diesel and aviation turbine fuel export duty

India Increases Export Duty on Diesel and Aviation Turbine Fuel to Boost Revenue

November 17, 2026
Photos: California residents gather to watch massive El Nino-fuelled waves

Massive El Niño Waves Draw California Residents to Coastal Viewing Spots

November 17, 2026

You Might Also Like

66% of births in 2024 were first-borns; birth spacing for majority now 36 months
Nation

2024 Sees 66% of Births as First-Children, Average Birth Spacing Now 36 Months

3 Min Read
Friday Focus: Adani Group and 12 stocks to track on September 19
Economy

Adani Group Spotlight: 12 Must-Track Stocks on September 19

6 Min Read
Appointed, ignored & unpaid: Meet India's 'invisible' teachers
Nation

Unseen Educators: Exploring India’s Unpaid and Overlooked Teachers’ Struggles

6 Min Read
Trump and I both put nation first, that’s our connect: PM Modi
Nation

PM Modi: Trump and I Share a Common Vision for Our Nations

6 Min Read

About IndiaNewsWeek

IndiaNewsWeek is your trusted source for breaking news, in-depth analysis, and comprehensive coverage of India and the world. We deliver accurate, timely reporting across politics, economy, sports, entertainment, and technology.

contact@indianewsweek.com

Quick Links

  • Nation
  • Politics
  • Economy
  • International
  • Sports
  • Entertainment

More Sections

  • Technology
  • Auto News
  • Education
  • About Us
  • Contact
  • Privacy Policy

Stay Connected

Follow us on social media for the latest updates and breaking news.

Facebook
X (Twitter)
YouTube
Follow US
© 2026 IndiaNewsWeek. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?